Patents by Inventor Bianka Prinz

Bianka Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12162941
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 10, 2024
    Assignee: Surface Oncology, LLC
    Inventors: Bianka Prinz, Nadthakarn Boland, Kevin Schutz, John Bukowski, Jennifer Symonds, James Mohan, Marisella Panduro Sicheva
  • Patent number: 12161717
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 10, 2024
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • Patent number: 12162949
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: December 10, 2024
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Publication number: 20240400676
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
    Type: Application
    Filed: May 6, 2024
    Publication date: December 5, 2024
    Inventors: Daniel Tavares, Bianka Prinz, James Geoghegan
  • Patent number: 12134648
    Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 5, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland, Eric Krauland
  • Patent number: 12129300
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 29, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Publication number: 20240309101
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Application
    Filed: September 20, 2023
    Publication date: September 19, 2024
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Patent number: 12084651
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 10, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Publication number: 20240270867
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Application
    Filed: March 20, 2024
    Publication date: August 15, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Carlo TONIATTI, Bianka PRINZ, Nadthakarn BOLAND
  • Patent number: 12049499
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to CD19, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: July 30, 2024
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Daniel Tavares, Bianka Prinz, James Geoghegan
  • Publication number: 20240228625
    Abstract: Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 11, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
  • Patent number: 11976128
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 7, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland
  • Patent number: 11939384
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: March 26, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Publication number: 20240092928
    Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 21, 2024
    Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
  • Publication number: 20240076385
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 7, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Publication number: 20240076384
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 7, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Publication number: 20240067735
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Application
    Filed: November 3, 2023
    Publication date: February 29, 2024
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Publication number: 20240043538
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Application
    Filed: November 17, 2022
    Publication date: February 8, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Carlo TONIATTI, Ashvin R. JAISWAL, Dongxing ZHA, Kui VOO, Bianka PRINZ, Nadthakarn BOLAND
  • Patent number: 11884733
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Patent number: 11884732
    Abstract: Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz